Released : October 23, 2019 07:01 RNS Number : 8257Q MaxCyte, Inc. 23 October 2019 MaxCyte Announces Presentations at 5th Annual Cell & Gene Therapy Congress Highlighting Unique Promise of Its Technology Gaithersburg, Maryland - 23 October 2019 - MaxCyte (LSE: MXCT, MXCS), the global
Released : October 08, 2019 07:00 RNS Number : 0594P MaxCyte, Inc. 08 October 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notification of Annual General Meeting and Declaration of Audit Remuneration Gaithersburg, MD - 08 October 2019: MaxCyte (LSE: MXCT, MXCR), the global
Released : October 07, 2019 07:00 RNS Number : 9473O MaxCyte, Inc. 07 October 2019 Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines CAMBRIDGE, Mass. , and GAITHERSBURG, Md. , October 7, 2019 - Editas Medicine, Inc.
Released : September 18, 2019 07:00 RNS Number : 6880M MaxCyte, Inc. 18 September 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2019 ¾ Strong commercial execution and financial performance with 21% year-over-year revenue growth ¾ Cell
Released : September 09, 2019 07:00 RNS Number : 5829L MaxCyte, Inc. 09 September 2019 MaxCyte Announces Presentation at ICLE 2019 Gaithersburg, Maryland - 9 September 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company , announces today that
Released : August 14, 2019 07:00 RNS Number : 9483I MaxCyte, Inc. 14 August 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Gaithersburg, Maryland - 14 August 2019: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based therapies and life
Released : July 17, 2019 07:00 RNS Number : 7557F MaxCyte, Inc. 17 July 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Significant CARMA™ programme progress, 80+ partnered programmes licensed and strong financial performance with 21% year over year revenue growth
Released : July 11, 2019 07:00 RNS Number : 1593F MaxCyte, Inc. 11 July 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte to Host Capital Markets Day Today Gaithersburg, Maryland - 11 July 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences
Released : July 05, 2019 16:42 RNS Number : 7002E MaxCyte, Inc. 05 July 2019 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
